Rachel Klemovitch, Assistant Editor02.28.24
Dave Hickey, executive vice president and president of the Life Sciences segment of BD, has announced his intent to retire effective July 1, 2024.
Hickey has held his current position since January of 2021. Before heading Life Sciences, he served as president of Integrated Diagnostics Solutions as well as president of Diagnostic Systems. Prior to BD Hickey worked at Siemens Healthcare in a variety of positions.
"For over a decade at BD, Dave has demonstrated a strong, strategic and innovative approach, empowering his teams to deliver impactful results through a growth mindset and developing incredible talent and next-gen leaders at BD," BD chairman, CEO and president, Tom Polen said. "I want to express BD's sincere gratitude to Dave for his significant contributions to BD, especially during the COVID-19 pandemic, where he led the BD effort to develop numerous rapid and molecular diagnostic tests in record time to support health care providers and patients around the world. We wish him all the best in his well-deserved retirement."
BD has yet to name a successor, as one will be announced closer to Hickey’s retirement date.
Hickey commented: "Throughout my career, I've been most driven by the people I have had the privilege to lead, and the important work we've done to help patients around the world. In my 10 years at BD, I've worked alongside some of the most incredible and talented teams in MedTech who have delivered countless research and diagnostic innovations, and who are having a profound impact on people around the world. I'm incredibly proud of what we've accomplished together and am confident in the continued success of BD now and in the future."
Hickey has held his current position since January of 2021. Before heading Life Sciences, he served as president of Integrated Diagnostics Solutions as well as president of Diagnostic Systems. Prior to BD Hickey worked at Siemens Healthcare in a variety of positions.
"For over a decade at BD, Dave has demonstrated a strong, strategic and innovative approach, empowering his teams to deliver impactful results through a growth mindset and developing incredible talent and next-gen leaders at BD," BD chairman, CEO and president, Tom Polen said. "I want to express BD's sincere gratitude to Dave for his significant contributions to BD, especially during the COVID-19 pandemic, where he led the BD effort to develop numerous rapid and molecular diagnostic tests in record time to support health care providers and patients around the world. We wish him all the best in his well-deserved retirement."
BD has yet to name a successor, as one will be announced closer to Hickey’s retirement date.
Hickey commented: "Throughout my career, I've been most driven by the people I have had the privilege to lead, and the important work we've done to help patients around the world. In my 10 years at BD, I've worked alongside some of the most incredible and talented teams in MedTech who have delivered countless research and diagnostic innovations, and who are having a profound impact on people around the world. I'm incredibly proud of what we've accomplished together and am confident in the continued success of BD now and in the future."